Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis (Adv. Sci. 30/2023)

Bispecific Antibodies In article number 2303908, Quan Zhou, Lisong Teng, and co‐workers developed a bispecific antibody (BsAb) that targets both PD1 in T cells and Her2 in tumor cells. This BsAb acts like a handcuff, firmly locking Her2(+) tumor cells in the hands of CD8(+) T cell policemen within the body. With the assistance of this handcuff, the CD8(+) T cell policemen form an immune synapse with the tumor cells and unleash bullets (such as granzyme A), causing the pyroptosis of the tumor cells. Moreover, the pyroptotic tumor cells release inflammatory cytokines, attracting more CD8(+) T cell policemen to raise their guns, significantly enhancing the effectiveness against HER2(+) tumors. [Image: see text]